Management of Organophosphate (OPC) Poisoning - ER to Discharge

1. Recognition - Cholinergic Toxidrome

OPC poisons acetylcholinesterase, causing accumulation of acetylcholine at all synapses. Remember two mnemonics:

SLUDGE (Muscarinic effects):

Salivation, Lacrimation, Urination, Diarrhea, GI cramps, Emesis

(Killer) Bs:

Bradycardia, Bronchorrhea, Bronchospasm (the lethal triad)

Nicotinic effects (neuromuscular): Muscle fasciculations, weakness, paralysis, tachycardia, hypertension, pallor

CNS effects: Tremor, headache, dizziness, confusion, seizures, coma

Death is almost always due to respiratory failure from bronchorrhea + respiratory muscle paralysis combined.

2. Initial Stabilization (Simultaneous Steps)

A. Protect Yourself and Decontaminate

All healthcare workers must wear level C PPE - full-face air-purifying mask, chemical-resistant suit, nitrile/butyl rubber gloves (NOT latex)
Remove and bag all clothing - the single most important decontamination step
Wash skin/scalp/hair/fingernails/skin folds/conjunctivae with copious mild detergent and water; avoid skin abrasion
Equipment can be decontaminated with 5% hypochlorite, but NOT skin
GI decontamination (gastric lavage, activated charcoal) is NOT beneficial - organophosphates are rapidly absorbed and profuse vomiting/diarrhea have already occurred

B. Airway and Breathing (Priority #1)

Place on 100% non-rebreather mask; do not delay atropine waiting for oxygen
Suction secretions aggressively
Intubate early if: coma, seizures, respiratory failure, severe bronchorrhea, excessive secretions, severe bronchospasm
For RSI, use rocuronium 1 mg/kg (preferred) - succinylcholine is metabolized by cholinesterases and may cause prolonged paralysis of 4-6 hours in OPC poisoning
Establish IV access; draw baseline blood including plasma/RBC cholinesterase levels before antidotes

C. Monitoring

Cardiac monitor + pulse oximetry
Baseline labs: cholinesterase levels, ABG, electrolytes, renal/liver function, blood glucose, ECG (QTc prolongation can occur)

3. Antidote Therapy

A. Atropine - First and Most Important

Atropine competitively blocks acetylcholine at muscarinic receptors (reverses SLUDGE + bronchorrhea/bronchospasm/bradycardia). It does NOT reverse nicotinic effects (muscle paralysis, fasciculations).

Goal of atropinization: Dry the lungs (chest clear on auscultation) - NOT pupil dilatation

Parameter	Adult	Pediatric
Initial dose	1.2-3 mg IV (or 2-6 mg IM if no IV access)	0.05 mg/kg IV
Escalation	Double the dose every 5 minutes	Same
Maintenance infusion	10-20% of total loading dose per hour	Same approach
Typical total dose in massive ingestion	200-500 mg in the first hour	Variable

Endpoints of atropinization (ALL must be met):

Chest clear on auscultation (bronchorrhea resolved)
Heart rate >80 beats/min
Systolic BP >80 mmHg
Reduction in secretions

Important notes:

Tachycardia and mydriasis are NOT contraindications to continued atropine - tachycardia can be from hypoxia/bronchospasm
Pupillary dilatation is NOT a therapeutic endpoint
Absence of anticholinergic symptoms after the initial dose confirms severe OPC poisoning
Anticholinergic toxidrome (hyperthermia, absent bowel sounds, delirium) = over-atropinization - reduce infusion rate
Glycopyrrolate can substitute but dosing is less defined; no proven benefit over atropine

B. Pralidoxime (2-PAM) - Oxime Reactivator

Pralidoxime binds the organophosphate-cholinesterase complex and regenerates functional acetylcholinesterase, reversing both muscarinic AND nicotinic effects including muscle paralysis.

Critical: Must be given before "aging" occurs (irreversible covalent binding of OPC to cholinesterase). Aging time varies by agent (minutes for soman, hours-days for parathion/malathion).

Dosing regimen	Adult	Pediatric
WHO recommended	30 mg/kg IV bolus, then 8 mg/kg/h infusion	Same
US alternative	1-2 g IV over 30 min, repeat hourly as needed	25-50 mg/kg IV over 30 min
Another alternative	2 g bolus over 20 min, then 500 mg/h for up to 7 days	-

Indications (moderate-severe poisoning):

Respiratory depression or failure
Muscle fasciculations
Seizures
Dysrhythmias
Hemodynamic instability
Requiring large/repeated doses of atropine

Pralidoxime is NOT indicated in: asymptomatic patients or known carbamate-only exposure with minimal symptoms (carbamates do not "age" and resolve spontaneously)

Continue pralidoxime for 24-48 hours while monitoring cholinesterase levels. For fat-soluble OPCs (e.g., fenthion), infusion may be needed for weeks pending enzyme resynthesis.

4. Management of Complications

Complication	Treatment
Seizures	Airway protection + oxygen + atropine + benzodiazepines (IV diazepam/lorazepam first line)
Bronchospasm/pulmonary edema	O2, intubation, IPPV, atropine, pralidoxime
Hypotension	Isotonic crystalloid boluses first
Tachyarrhythmias	Treat the underlying cholinergic excess - do NOT use beta-blockers
Agitation/coma	Benzodiazepines after airway secured

Drugs to AVOID:

Succinylcholine (prolonged paralysis)
Ester anesthetics
Beta-adrenergic blockers
No role for hemodialysis/hemoperfusion/hemofiltration

5. Intermediate Syndrome (IMS) - Watch for This

Occurs 1-5 days (24-96 hours) after the cholinergic crisis resolves, in up to 40% of patients following ingestion
Features: paralysis of neck flexors, cranial nerve-innervated muscles, proximal limb muscles, and respiratory muscles
Cholinergic signs are ABSENT in IMS
Respiratory support may be needed
EMG may help confirm diagnosis
Resolves in ~7 days with supportive care
Aggressive early antidote therapy may reduce severity

6. Disposition

Severity	Disposition
Asymptomatic / minimal exposure, normal or near-normal cholinesterase	Observe for 6 hours in ED; if stable, discharge with close outpatient follow-up
Significant symptoms (seizures, respiratory compromise, depressed cholinesterase)	Admit to ICU with continuous monitoring
Rebound toxicity concern (fat-soluble agents like fenthion, lipid redistribution)	Prolonged admission; anticipate delayed worsening

7. Criteria Before Discharge

No cholinergic symptoms at rest
Spontaneous breathing adequate (no respiratory muscle weakness)
Pralidoxime successfully weaned - absence of signs/symptoms on withholding pralidoxime
Cholinesterase levels trending upward
Monitored for IMS window (minimum 5 days in significant ingestions)
Psychiatric consultation completed if poisoning was a self-harm or suicidal attempt
Patient counseled: re-exposure even at low doses causes cumulative toxicity - must avoid further exposure until cholinesterase activity normalizes

Summary Flow

Exposure → Decontaminate (PPE, remove clothes, wash skin)
         ↓
Airway/O2 (suction, intubate early, rocuronium for RSI)
         ↓
Atropine (1-3 mg IV, double every 5 min → endpoint: dry lungs, HR>80, SBP>80)
         ↓
Atropine infusion (10-20% of loading dose/hr)
         ↓
Pralidoxime (1-2 g IV over 30 min → infusion 8 mg/kg/h or 500 mg/h)
         ↓
Treat seizures with benzodiazepines
         ↓
ICU monitoring → watch for IMS days 1-5
         ↓
Wean pralidoxime → confirm no rebound → discharge with psychiatric referral if needed

Sources: Rosen's Emergency Medicine (9th ed.), Tintinalli's Emergency Medicine (9th ed.), Harriet Lane Handbook (23rd ed.) - all accessed from the medical library.

Recent evidence note: A 2026 umbrella review (PMID 42258859) and a 2025 systematic review on glycopyrrolate (PMID 38797902) are the most recent publications; the glycopyrrolate review found insufficient evidence to recommend it over atropine, consistent with the textbook guidance above.

This is a shared conversation. Sign in to Orris to start your own chat.